We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 22, 2021

Better QOL With Lower-Dose Nab-Paclitaxel

Breast Cancer (Tokyo, Japan)


Additional Info

Disclosure statements are available on the authors' profiles:

Breast Cancer (Tokyo, Japan)
Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
Breast Cancer 2021 Sep 07;[EPub Ahead of Print], N Taira, K Kashiwabara, J Tsurutani, M Kitada, M Takahashi, H Kato, Y Kikawa, E Sakata, Y Naito, Y Hasegawa, T Saito, T Iwasa, T Takashima, T Aihara, H Mukai, F Hara

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading